{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:57:03Z","timestamp":1792036623615,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A patient reported outcome (PRO) instrument with evidence of validity and reliability for assessing symptoms of eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE) is needed to measure treatment benefit in clinical trials. The aim of this research is to develop an EG\/EGE symptom PRO instrument for patients aged 12 and above.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Symptom Assessment for Gastrointestinal Eosinophilic Diseases (SAGED) was developed through a literature review, discussions with expert clinicians, and concept elicitation and cognitive debriefing interviews with patients. Patients (n\u2009=\u200928) were recruited based on confirmed diagnosis and self-reported symptoms. The final instrument was translated and linguistically validated with additional cognitive debriefing interviews (n\u2009=\u2009105).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SAGED is a 24-h recall questionnaire consisting of eight items evaluating the core symptoms of EG and EGE (abdominal pain, nausea, bloating, early satiety, loss of appetite, vomiting, and diarrhea). Seven of the eight items are evaluated on an 11-point numerical rating scale ranging from \u2018none\u2019 to \u2018worst imaginable\u2019. Cognitive debriefing interviews showed that adults and adolescents understand the content and are able to select a response that reflects their experience. The linguistic validation process produced 21 translations that are understandable to patients and conceptually equivalent to the source version.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>SAGED is suitable for measuring symptom improvement in adult and adolescent patients with EG and\/or EGE. The content validity of SAGED has been established through best practices in qualitative research for PRO instrument development. The psychometric properties of SAGED will be evaluated in a future study.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-02107-6","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T12:03:17Z","timestamp":1637755397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-9651","authenticated-orcid":false,"given":"Calvin N.","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"O\u2019Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley F.","family":"Slagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S.","family":"Dellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Datto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"issue":"1","key":"2107_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/MPG.0000000000000865","volume":"62","author":"ET Jensen","year":"2016","unstructured":"Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a national administrative database. J Pediatr Gastroenterol Nutr. 2016;62(1):36\u201342.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"9","key":"2107_CR2","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s10620-016-4203-5","volume":"61","author":"T Alhmoud","year":"2016","unstructured":"Alhmoud T, Hanson JA, Parasher G. Eosinophilic gastroenteritis: an underdiagnosed condition. Dig Dis Sci. 2016;61(9):2585\u201392.","journal-title":"Dig Dis Sci"},{"key":"2107_CR3","doi-asserted-by":"crossref","unstructured":"Talley NJ, Kamboj AP, Chey WD, et al. Endoscopy and systematic biopsy of patients with chronic gastrointestinal symptoms leads to high discovery rate of patients who meet histologic criteria for eosinophilic gastritis and\/or eosinophilic duodenitis. Gastroenterology. 2021;160(6):S-110\u2013111.","DOI":"10.1016\/S0016-5085(21)01011-8"},{"issue":"5","key":"2107_CR4","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.jaip.2020.12.054","volume":"9","author":"M Chehade","year":"2021","unstructured":"Chehade M, Kamboj AP, Atkins D, Gehman LT. Diagnostic delay in patients with eosinophilic gastritis and\/or duodenitis: a population-based study. J Allergy Clin Immunol Pract. 2021;9(5):2050-2059.e2020.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"2107_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00005792-197007000-00003","volume":"49","author":"NC Klein","year":"1970","unstructured":"Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis. Medicine. 1970;49(4):299\u2013319.","journal-title":"Medicine"},{"key":"2107_CR6","doi-asserted-by":"crossref","unstructured":"Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allerg Clin Immunol. 2004;113(1):11\u201328.","DOI":"10.1016\/j.jaci.2003.10.047"},{"issue":"3","key":"2107_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.dld.2014.11.009","volume":"47","author":"C Reed","year":"2015","unstructured":"Reed C, Woosley JT, Dellon ES. Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis. Digest Liver Dis. 2015;47(3):197\u2013201.","journal-title":"Digest Liver Dis"},{"issue":"6","key":"2107_CR8","doi-asserted-by":"publisher","first-page":"984","DOI":"10.14309\/ajg.0000000000000228","volume":"114","author":"RD Pesek","year":"2019","unstructured":"Pesek RD, Reed CC, Muir AB, et al. Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium. Am J Gastroenterol. 2019;114(6):984\u201394.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2107_CR9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/ajg.2014.166","volume":"109","author":"HM Ko","year":"2014","unstructured":"Ko HM, Morotti RA, Yershov O, Chehade M. Eosinophilic gastritis in children: clinicopathological correlation, disease course, and response to therapy. Am J Gastroenterol. 2014;109(8):1277\u201385.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2107_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12016-015-8489-4","volume":"50","author":"V Uppal","year":"2016","unstructured":"Uppal V, Kreiger P, Kutsch E. Eosinophilic gastroenteritis and colitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(2):175\u201388.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2107_CR11","doi-asserted-by":"crossref","unstructured":"Naramore S, Gupta SK. Nonesophageal eosinophilic gastrointestinal disorders: clinical care and future directions. J Pediat Gastroenterol Nutrit. 2018;67(3).","DOI":"10.1097\/MPG.0000000000002040"},{"issue":"2","key":"2107_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.anai.2018.06.013","volume":"121","author":"M Egan","year":"2018","unstructured":"Egan M, Furuta GT. Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2018;121(2):162\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"2107_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S2468-1253(18)30005-0","volume":"3","author":"MM Walker","year":"2018","unstructured":"Walker MM, Potter M, Talley NJ. Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus. Lancet Gastroenterol Hepatol. 2018;3(4):271\u201380.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2107_CR14","doi-asserted-by":"crossref","unstructured":"E K, A P. Eosinophilic gastrointestinal diseases in childhood. Ann Nutr Metab. 2018;73:18\u201328.","DOI":"10.1159\/000493668"},{"issue":"5","key":"2107_CR15","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1007\/s10620-018-4978-7","volume":"63","author":"A Bedell","year":"2018","unstructured":"Bedell A, Taft T, Craven MR, Guadagnoli L, Hirano I, Gonsalves N. Impact on health-related quality of life in adults with eosinophilic gastritis and gastroenteritis: a qualitative assessment. Dig Dis Sci. 2018;63(5):1148\u201357.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"2107_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.4292\/wjgpt.v7.i4.513","volume":"7","author":"A Abou Rached","year":"2016","unstructured":"Abou Rached A, El Hajj W. Eosinophilic gastroenteritis: approach to diagnosis and management. World J Gastrointest Pharmacol Ther. 2016;7(4):513\u201323.","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"2","key":"2107_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.gtc.2014.02.013","volume":"43","author":"C Prussin","year":"2014","unstructured":"Prussin C. Eosinophilic gastroenteritis and related eosinophilic disorders. Gastroenterol Clin North Am. 2014;43(2):317\u201327.","journal-title":"Gastroenterol Clin North Am"},{"key":"2107_CR18","doi-asserted-by":"crossref","unstructured":"Gonsalves N, Doerfler B, Zalewski A, et al. Results from the element study: Prospective study of elemental diet in eosinophilic gastroenteritis nutrition trial. Gastroenterology. 2020;158(6):S-43.","DOI":"10.1016\/S0016-5085(20)30790-3"},{"issue":"1","key":"2107_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/MPG.0000000000000766","volume":"61","author":"AJ Lucendo","year":"2015","unstructured":"Lucendo AJ, Serrano-Montalb\u00e1n B, Arias \u00c1, Redondo O, Tenias JM. Efficacy of dietary treatment for inducing disease remission in eosinophilic gastroenteritis. J Pediatr Gastroenterol Nutr. 2015;61(1):56\u201364.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"11","key":"2107_CR20","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216\u201329.","journal-title":"Clin Ther"},{"issue":"9","key":"2107_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11882-015-0558-5","volume":"15","author":"A Cianferoni","year":"2015","unstructured":"Cianferoni A, Spergel JM. Eosinophilic esophagitis and gastroenteritis. Curr Allergy Asthma Rep. 2015;15(9):58.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"6","key":"2107_CR22","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/jgh.13281","volume":"31","author":"AR Murali","year":"2016","unstructured":"Murali AR, Gupta A, Attar BM, Ravi V, Koduru P. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled randomized clinical trials. J Gastroenterol Hepatol. 2016;31(6):1111\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"2107_CR23","doi-asserted-by":"crossref","unstructured":"Chuang M-YA, Chinnaratha MA, Hancock DG, et al. Topical Steroid Therapy for the Treatment of Eosinophilic Esophagitis (EoE): A systematic review and meta-analysis. Clin Transl Gastroenterol. 2015;6(3):e82-e82.","DOI":"10.1038\/ctg.2015.9"},{"issue":"1","key":"2107_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","volume":"157","author":"AJ Lucendo","year":"2019","unstructured":"Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157(1):74-86.e15.","journal-title":"Gastroenterology"},{"issue":"7","key":"2107_CR25","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.cgh.2012.03.018","volume":"10","author":"JA Alexander","year":"2012","unstructured":"Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012;10(7):742-749.e741.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2107_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.gtc.2014.02.007","volume":"43","author":"MH Collins","year":"2014","unstructured":"Collins MH. Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases. Gastroenterol Clin North Am. 2014;43(2):257\u201368.","journal-title":"Gastroenterol Clin North Am"},{"key":"2107_CR27","unstructured":"Food and Drug Administration. Eosinophilic Esophagitis: Developing Drugs for Treatment Guidance for Industry. 2020; https:\/\/www.fda.gov\/media\/120089\/download."},{"key":"2107_CR28","unstructured":"Food and Drug Administration. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009; https:\/\/www.fda.gov\/media\/77832\/download."},{"key":"2107_CR29","unstructured":"Food and Drug Administration. Patient-focused drug development guidance public workshop: Methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. 2018; https:\/\/www.fda.gov\/media\/116277\/download."},{"issue":"8","key":"2107_CR30","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1524-4733.2009.00603.x","volume":"12","author":"M Rothman","year":"2009","unstructured":"Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. Val Health. 2009;12(8):1075\u201383.","journal-title":"Val Health"},{"issue":"8","key":"2107_CR31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument. Val Health. 2011;14(8):967\u201377.","journal-title":"Val Health"},{"issue":"8","key":"2107_CR32","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2013assessing respondent understanding. Val Health. 2011;14(8):978\u201388.","journal-title":"Val Health"},{"key":"2107_CR33","volume-title":"Discovery of Grounded Theory: Strategies for Qualitative Research","author":"BG Glaser","year":"1967","unstructured":"Glaser BG, Strauss AL. Discovery of Grounded Theory: Strategies for Qualitative Research. New York: Aldine De Gruyter; 1967."},{"issue":"9","key":"2107_CR34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s11136-009-9540-9","volume":"18","author":"M Brod","year":"2009","unstructured":"Brod M, Tesler LE, Christensen TL. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res. 2009;18(9):1263.","journal-title":"Qual Life Res"},{"issue":"2","key":"2107_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","volume":"8","author":"D Wild","year":"2005","unstructured":"Wild D, Grove A, Martin M, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation. Value in Health. 2005;8(2):94\u2013104.","journal-title":"Value in Health"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-02107-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T12:17:54Z","timestamp":1637756274000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-02107-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2107"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-02107-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study materials were reviewed and approved by the New England Institutional Review Board in November 2018 and July 2019. All patients gave their informed consent to be included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients gave their informed consent for the results of the study to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ESD has received research funding from AstraZeneca, Adare\/Ellodi, Allakos, Arena, GSK, Meritage, Miraca, Nutricia, Celgene\/Receptos\/BMS, Regeneron, and Shire\/Takeda, and educational grants from Allakos, Banner, and Holoclara. ESD has also served as a consultant for AstraZeneca, Abbott, Abbvie, Adare\/Ellodi, Aimmune, Allakos, Amgen, Arena, Avir, Biorasi, Calypso, Celgene\/Receptos\/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Holoclara, Landos, Morphic, Nutricia, Parexel\/Calyx, Regeneron, Revolo, Robarts\/Alimentiv, Salix, Sanofi, and Shire\/Takeda. CNH, SOQ, and CD are employees of and own stocks and shares in AstraZeneca. JRB and OM are employees of IQVIA Real World Solutions, Patient Centered Solutions, which received funding from AstraZeneca to complete the study. AFS has served as a consultant for IQVIA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"495"}}